Search results
Showing 1051 to 1065 of 1961 results for nice guidelines
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)
Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..
NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .
Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.
Percutaneous laser revascularisation for refractory angina pectoris (HTG193)
Evidence-based recommendations on percutaneous laser revascularisation for refractory angina pectoris. This involves inserting a catheter into major vessels of the groin, which is advanced to the heart, to drill holes on the heart muscle using a laser beam.
View recommendations for HTG193Show all sections
Sections for HTG193
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)
NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Axumin for functional imaging of prostate cancer recurrence (MIB172)
NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .
In development Reference number: GID-TA11960 Expected publication date: 24 February 2027
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.